View Older Stories View More Recent Stories

May 13, 2020 05:00PM Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting
May 7, 2020 11:47AM Gilead Sciences (GILD) Confirms Approval of Remdesivir in Japan for Patients With Severe COVID-19
May 7, 2020 11:45AM Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
May 1, 2020 04:23PM Gilead (GILD) sets goal of producing at least 500,000 treatment courses of remdesivir by October
May 1, 2020 04:19PM Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19
Apr 30, 2020 04:02PM Gilead Sciences Announces Second Quarter 2020 Dividend
Apr 29, 2020 08:38AM Gilead Sciences (GILD) Phase 3 Trial of Remdesivir in Severe COVID-19 Patients Shows Improvement
Apr 29, 2020 08:35AM Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19
Apr 16, 2020 05:30PM Gilead Sciences to Release First Quarter 2020 Financial Results on Thursday, April 30, 2020
Apr 15, 2020 04:15PM Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions
Apr 11, 2020 10:48AM Gilead Sciences (GILD) Remdesivir Study Shows Two-Third of Severe COVID-19 Patients Improved
Apr 10, 2020 03:31PM Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine
Apr 8, 2020 01:09PM Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis
Apr 7, 2020 08:32AM Gilead Sciences (GILD) Completes Forty Seven (FTSV) Acquisition
Apr 7, 2020 08:32AM Gilead Completes Acquisition of Forty Seven, Inc.
Mar 30, 2020 08:31AM Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer
Mar 30, 2020 08:30AM Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer
Mar 19, 2020 02:41PM Gilead (GILD) Announces FDA Approval for Epclusa for Children Ages 6 and Older with HCV
Mar 19, 2020 02:40PM U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
Mar 11, 2020 03:12PM Gilead Sciences (GILD) Announces New Clinical Study Data for its Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
Mar 11, 2020 03:09PM New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
Mar 10, 2020 02:34PM Gilead (GILD) Announces Treatment With its Vesatolimod is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study
Mar 10, 2020 02:33PM Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study
Mar 10, 2020 11:32AM Gilead Sciences (GILD) Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations
Mar 10, 2020 11:32AM Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations
Mar 9, 2020 02:53PM New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
Mar 5, 2020 01:02AM Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2019 RESULTS AND 2020 OUTLOOK
Mar 2, 2020 09:24AM Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
Feb 26, 2020 05:00PM Gilead Sciences (GILD) Initiates Two Phase 3 Studies of Remdesivir for Treatment of COVID-19
Feb 26, 2020 05:00PM Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
Feb 25, 2020 10:15AM U.S. health officials urge Americans to prepare for spread of coronavirus
Feb 19, 2020 08:30AM Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center
Feb 18, 2020 08:00PM Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020
Feb 10, 2020 08:33AM Gilead Sciences (GILD) Announces FDA Grants Priority Review for Kite's KTE-X19 BLA in R/R Mantle Cell Lymphoma
Feb 10, 2020 08:30AM U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma
Feb 4, 2020 04:02PM Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend
Jan 30, 2020 04:05PM Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors
Jan 28, 2020 04:15PM European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy
Jan 21, 2020 05:30PM Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020
Jan 13, 2020 05:45AM Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Jan 9, 2020 08:31AM Gilead Sciences (GILD) Licenses Portfolio of HIV Antibodies From The Rockefeller University
Jan 9, 2020 08:30AM Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
Jan 9, 2020 07:37AM Scholar Rock Holding Corp. (SRRK) Reports $25M Milestone Payment from Strategic Fibrosis Collaboration with Gilead Sciences (GILD)
Jan 9, 2020 07:30AM Scholar Rock Achieves First Milestone in Strategic Fibrosis Collaboration with Gilead Sciences
Dec 23, 2019 08:01AM Gilead Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020
Dec 20, 2019 08:31AM Gilead Sciences (GILD) Announces China NMPA Approves Vosevi for People With Chronic Hepatitis C Infection Who Require Re-Treatment
Dec 20, 2019 08:30AM China National Medical Products Administration Approves Vosevi® (Sofosbuvir, Velpatasvir and Voxilaprevir) for People With Chronic Hepatitis C Infection Who Require Re-Treatment
Dec 19, 2019 04:30PM Gilead Sciences (GILD) Submits Filgotinib NDA to FDA Under Priority Review for Rheumatoid Arthritis Treatment
Dec 19, 2019 04:30PM Gilead Submits Filgotinib New Drug Application to U.S. Food and Drug Administration Under Priority Review for Rheumatoid Arthritis Treatment
Dec 16, 2019 08:03AM Gilead Sciences (GILD) Announces Topline Results From Phase 2 ATLAS Study in Patients With Bridging Fibrosis and Compensated Cirrhosis Due to NASH
View More Recent Stories View Older Stories